Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05970237 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 15, 2025 (before its estimated October 21, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary and study completion dates: Jun 2025 to Oct 21, 2025v4
  2. Primary and study completion dates: Dec 2024 to Jun 2025v3
  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jul 2023 to Jul 26, 2023 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Jul 2023 to Jul 26, 2023
    • Site details revised
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this clinical trial is to evaluate the efficacy and safety of dapagliflozin in patient with type 2 diabetes mellitus and hypertension
Trial Details
NCT Number NCT05970237
Lead Sponsor Boryung Pharmaceutical Co., Ltd
Conditions Diabetes Mellitus, Hypertension
Enrollment 9,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov